Vivos Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Vivos Therapeutics generated cash of -$11,946,000, which is more than the previous year. Cash used in financing activities reached the amount of $10,923,000 last year. Net change in cash is therefore -$1,876,000.
Cash Flow
| 2018 | -5.31M | -1.11M | 5.25M |
|---|---|---|---|
| 2019 | -5.34M | 86.22K | 4.46M |
| 2020 | -5.68M | -120.25K | 23.53M |
| 2021 | -15.73M | -2.60M | 24.16M |
| 2022 | -19.58M | -924K | 0 |
| 2023 | -11.94M | -853K | 10.92M |
VVOS Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 3.51M | 24.03M | 18.20M | 469.35K | 1.25M | 2.43M |
Operating activities | ||||||
Net income | -13.58M | -23.84M | -20.28M | -12.05M | -10.75M | -8.43M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 621K | 669K | 733K | 717.86K | 751.22K | 610.67K |
Stock-based compensation expense | 0 | 2.39M | 2.65M | 2.17M | 1.98M | 0 |
| Deferred income tax benefit | 0 | 2.39M | 2.65M | 2.17M | 1.98M | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 255K | 746K | 228K | -559.6K | -276.10K | -530.28K |
Inventories | 0 | 0 | 168K | 332.59K | 401.01K | 0 |
Accounts payable | 734K | 491K | 139K | -274.21K | 547.62K | 246.53K |
Cash generated by operating activities | -11.94M | -19.58M | -15.73M | -5.68M | -5.34M | -5.31M |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -853K | -924K | -2.39M | -120.25K | -175.59K | -1.25M |
Acquisitions Net | 0 | 0 | -225K | 0 | 250K | 133.33K |
Cash generated by investing activities | -853K | -924K | -2.60M | -120.25K | 86.22K | -1.11M |
Financing activities | ||||||
Common Stock Issued | 12M | 0 | 25.69M | 22.28M | 1.24M | 6.35M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -1.5M | -2.15M | -350K | -1M |
Repayments of term debt | 0 | 0 | -25K | -75K | 3.73M | -88.23K |
Cash used in financing activities | 10.92M | 0 | 24.16M | 23.53M | 4.46M | 5.25M |
Net Change In Cash | -1.87M | -20.51M | 5.82M | 17.73M | -785.37K | -1.17M |
Cash at end of period | 1.64M | 3.51M | 24.03M | 18.20M | 469.35K | 1.25M |
| Data source | Data source | Data source | Data source |